Program
ALG-055009
A development code.
Its studies are mostly in Non-alcoholic Fatty Liver Disease, led by Aligos Therapeutics.
Furthest: phase 2, since Mar 15, 20244 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aligos Therapeutics | 40 open or running | phase 2since Mar 15, 2024 | Oct 11, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2021First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05090111 · 98 enrolled · France
- Nov 3, 2023Phase 1 study in Healthy VolunteersNCT06191991 · 14 enrolled · United States
- Mar 15, 2024Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06342947 · 102 enrolled · United States
- Mar 24, 2025Phase 1 study in Healthy Volunteer StudyNCT06959888 · 8 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06959888Healthy Volunteer Study · United States | 1 | Completed | May 8, 2025 | 8 |
| NCT06342947Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Aug 19, 2024 | 102 |
| NCT06191991Healthy Volunteers · United States | 1 | Completed | Nov 27, 2023 | 14 |
| NCT05090111Non-alcoholic Fatty Liver Disease · France | 1 | Completed | Jun 16, 2023 | 98 |
How it is read
Names in the registry
- “ALG-055009”, 4 entries
Codes read as this program: ALG055009.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.